Methods of current trials Several ongoing trials are investigating the anti-atherosclerotic effects of antihypertensive drugs in hypertensive patients. Changes in carotid intimal-medial thicknesses and atherosclerotic plaques are being explored by a sensitive quantitative B-mode ultrasound technique. Multicenter Isradipine/Diuretic Atherosclerosis Study (MIDAS) The results from this pioneering study indicated a slower progression, at least in the first 6 months, of carotid plaques in isradipine-treated patients than in diuretic-treated patients. MIDAS has been particularly valuable in giving information on the rate of growth of intimal-medial thickness in hypertensive patients and on the best end-point to use in carotid ultrasound trials. European Lacidipine Study on Atherosclerosis (ELSA) and Verapamil in Hypertension and Atherosclerosis Study (VHAS) Baseline data from these two ongoing studies have provided evidence of the very high prevalence of carotid lesions among hypertensive patients: the prevalence of plaques (defined as a carotid intimal-medial thickness of greater than or equal to 1.3 mm) was 83% in ELSA, while in VHAS, in which plaques were defined as an intimal-medial thickness of >1.5 mm), the plaque prevalence was 37%, These observations emphasize the importance of evaluating the atherosclerotic action of antihypertensive agents. Plaque Hypertension Lipid-Lowering Italian Study (PHYLLIS) This trial is using a factorial design to explore the anti-atherosclerotic action of an angiotensin converting enzyme (ACE) inhibitor (fosinopril) versus a diuretic, and also intends to evaluate the possible benefits of associating antihypertensive therapy with a statin to induce lipid-lowering to prevent the progression of carotid atherosclerosis.
机构:
Golestan Univ Med Sci, Ischem Disorders Res Ctr, Gorgan, Iran
Univ Tehran Med Sci, Fac Pharm, Dept Pharmacognosy, Tehran, Iran
Univ Tehran Med Sci, Med Plants Res Ctr, Tehran, IranGolestan Univ Med Sci, Ischem Disorders Res Ctr, Gorgan, Iran
Enayati, Ayesheh
Johnston, Thomas P.
论文数: 0引用数: 0
h-index: 0
机构:
Univ Missouri, Sch Pharm, Div Pharmacol & Pharmaceut Sci, Kansas City, MO USAGolestan Univ Med Sci, Ischem Disorders Res Ctr, Gorgan, Iran
机构:
Karolinska Inst, Inst Environm Med, Div Cardiovasc Epidemiol, S-10401 Stockholm, SwedenKarolinska Inst, Inst Environm Med, Div Cardiovasc Epidemiol, S-10401 Stockholm, Sweden
机构:
Ayurveda Res Ctr, Dept Pharm & Therapeut, Bombay 400012, Maharashtra, IndiaAyurveda Res Ctr, Dept Pharm & Therapeut, Bombay 400012, Maharashtra, India
Uchil, D. A.
Kamat, S. K.
论文数: 0引用数: 0
h-index: 0
机构:
Ayurveda Res Ctr, Dept Pharm & Therapeut, Bombay 400012, Maharashtra, IndiaAyurveda Res Ctr, Dept Pharm & Therapeut, Bombay 400012, Maharashtra, India
Kamat, S. K.
Vaideeswar, P. Z.
论文数: 0引用数: 0
h-index: 0
机构:
King Edward Mem Hosp, Bombay 400012, Maharashtra, India
Seth GS Med Coll, Dept Pathol, Bombay 400012, Maharashtra, IndiaAyurveda Res Ctr, Dept Pharm & Therapeut, Bombay 400012, Maharashtra, India
Vaideeswar, P. Z.
Soman, A. D.
论文数: 0引用数: 0
h-index: 0
机构:
Ayurveda Res Ctr, Dept Pharm & Therapeut, Bombay 400012, Maharashtra, IndiaAyurveda Res Ctr, Dept Pharm & Therapeut, Bombay 400012, Maharashtra, India
Soman, A. D.
Dhuri, S. A.
论文数: 0引用数: 0
h-index: 0
机构:
Ayurveda Res Ctr, Dept Pharm & Therapeut, Bombay 400012, Maharashtra, IndiaAyurveda Res Ctr, Dept Pharm & Therapeut, Bombay 400012, Maharashtra, India
Dhuri, S. A.
Scindia, A. M.
论文数: 0引用数: 0
h-index: 0
机构:
Ayurveda Res Ctr, Dept Pharm & Therapeut, Bombay 400012, Maharashtra, IndiaAyurveda Res Ctr, Dept Pharm & Therapeut, Bombay 400012, Maharashtra, India
Scindia, A. M.
Rege, N. N.
论文数: 0引用数: 0
h-index: 0
机构:
Ayurveda Res Ctr, Dept Pharm & Therapeut, Bombay 400012, Maharashtra, IndiaAyurveda Res Ctr, Dept Pharm & Therapeut, Bombay 400012, Maharashtra, India